Carbon ion irradiation of the human prostate cancer cell line PC3: A whole genome microarray study

Research output: Contribution to journalArticle

Standard

Carbon ion irradiation of the human prostate cancer cell line PC3: A whole genome microarray study. / Suetens, Annelies; Moreels, Marjan; Quintens, Roel; Chiriotti Alvarez, Sabina; Tabury, Kevin; Michaux, Arlette; Grégoire, Vincent; Baatout, Sarah.

In: International Journal of Oncology, Vol. 44, No. 4, 03.02.2014, p. 1056-1072.

Research output: Contribution to journalArticle

Bibtex - Download

@article{c9a5fcdc174f4d4ba7c4212a92a1d024,
title = "Carbon ion irradiation of the human prostate cancer cell line PC3: A whole genome microarray study",
abstract = "Hadrontherapy is a form of radiation therapy, which uses beams of charged particles such as carbon ions. Compared to conventional radiotherapy the main advantage of hadrontherapy is the precise dose-localization along with an increased biological effectiveness. First results obtained from prostate cancer patients treated withhadrontherapy showed good local tumor control and survival rates. We investigated the effects of irradiation with different beam qualities on gene expression changes in the PC3 prostate adenocarcinoma cell line. PC3 cells were irradiated with various doses of carbon ions (LET=33.7 keV/µm) at GANIL (Caen, France). Comparative experiments with X-rays were performed at SCK-CEN. Genome-wide expression was analyzed using microarrays. Our results show downregulation in many genes involved in cell cycle and cell organization after 2.0 Gy irradiation. This effect was more pronounced after carbon ion irradiation compared with X-rays. Furthermore, we found a significant downregulation of many genes related to cell motility. Several of these changes were confirmed using qPCR. In addition, recurrence-free survival analysis of prostate cancer patients based on one of these motility genes (FN1) revealed that patients with low expression levels had a prolonged recurrence-free survival time, indicating that this gene may be a potential prognostic biomarker for prostate cancer.",
keywords = "microarray, carbon ion therapy, motility genes, biomarkers, PC3 prostate adenocarcinoma",
author = "Annelies Suetens and Marjan Moreels and Roel Quintens and {Chiriotti Alvarez}, Sabina and Kevin Tabury and Arlette Michaux and Vincent Gr{\'e}goire and Sarah Baatout",
note = "Score = 10",
year = "2014",
month = "2",
day = "3",
doi = "10.3892/ijo.2014.2287",
language = "English",
volume = "44",
pages = "1056--1072",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

RIS - Download

TY - JOUR

T1 - Carbon ion irradiation of the human prostate cancer cell line PC3: A whole genome microarray study

AU - Suetens, Annelies

AU - Moreels, Marjan

AU - Quintens, Roel

AU - Chiriotti Alvarez, Sabina

AU - Tabury, Kevin

AU - Michaux, Arlette

AU - Grégoire, Vincent

AU - Baatout, Sarah

N1 - Score = 10

PY - 2014/2/3

Y1 - 2014/2/3

N2 - Hadrontherapy is a form of radiation therapy, which uses beams of charged particles such as carbon ions. Compared to conventional radiotherapy the main advantage of hadrontherapy is the precise dose-localization along with an increased biological effectiveness. First results obtained from prostate cancer patients treated withhadrontherapy showed good local tumor control and survival rates. We investigated the effects of irradiation with different beam qualities on gene expression changes in the PC3 prostate adenocarcinoma cell line. PC3 cells were irradiated with various doses of carbon ions (LET=33.7 keV/µm) at GANIL (Caen, France). Comparative experiments with X-rays were performed at SCK-CEN. Genome-wide expression was analyzed using microarrays. Our results show downregulation in many genes involved in cell cycle and cell organization after 2.0 Gy irradiation. This effect was more pronounced after carbon ion irradiation compared with X-rays. Furthermore, we found a significant downregulation of many genes related to cell motility. Several of these changes were confirmed using qPCR. In addition, recurrence-free survival analysis of prostate cancer patients based on one of these motility genes (FN1) revealed that patients with low expression levels had a prolonged recurrence-free survival time, indicating that this gene may be a potential prognostic biomarker for prostate cancer.

AB - Hadrontherapy is a form of radiation therapy, which uses beams of charged particles such as carbon ions. Compared to conventional radiotherapy the main advantage of hadrontherapy is the precise dose-localization along with an increased biological effectiveness. First results obtained from prostate cancer patients treated withhadrontherapy showed good local tumor control and survival rates. We investigated the effects of irradiation with different beam qualities on gene expression changes in the PC3 prostate adenocarcinoma cell line. PC3 cells were irradiated with various doses of carbon ions (LET=33.7 keV/µm) at GANIL (Caen, France). Comparative experiments with X-rays were performed at SCK-CEN. Genome-wide expression was analyzed using microarrays. Our results show downregulation in many genes involved in cell cycle and cell organization after 2.0 Gy irradiation. This effect was more pronounced after carbon ion irradiation compared with X-rays. Furthermore, we found a significant downregulation of many genes related to cell motility. Several of these changes were confirmed using qPCR. In addition, recurrence-free survival analysis of prostate cancer patients based on one of these motility genes (FN1) revealed that patients with low expression levels had a prolonged recurrence-free survival time, indicating that this gene may be a potential prognostic biomarker for prostate cancer.

KW - microarray

KW - carbon ion therapy

KW - motility genes

KW - biomarkers

KW - PC3 prostate adenocarcinoma

UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/ezp_134130

UR - http://knowledgecentre.sckcen.be/so2/bibref/11228

U2 - 10.3892/ijo.2014.2287

DO - 10.3892/ijo.2014.2287

M3 - Article

VL - 44

SP - 1056

EP - 1072

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -

ID: 209407